Regardless of the sequential decrease in Current Liabilities, during the first quarter 2026, Quick Ratio deteriorated to 4.4 below Soleno Therapeutics Inc's average Quick Ratio.

Within Medical Equipment & Supplies industry 31 other companies have achieved higher Quick Ratio than Soleno Therapeutics Inc in first quarter 2026. While Quick Ratio total ranking in the first quarter 2026 has deteriorated compared to the prior quarter from 272 to 686.

Explain Quick Ratio?
How much Cash & cash equivalents SLNO�s has?
What are SLNO�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

SLNO Quick Ratio	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2	(Mar 31 2025) Q1
Y / Y Current Liabilities Change	269.01 %	274.28 %	155.3 %	199.57 %	46.21 %
Y / Y Cash & cash equivalent Change	-11.85 %	4.82 %	94.31 %	7.79 %	93.78 %
Quick Ratio MRQ	4.4	4.98	15.33	13.7	18.43
SLNO's Total Ranking	# 686	# 272	# 174	# 100	# 81
Seq. Current Liabilities Change	-5.4 %	88.48 %	55.45 %	33.13 %	-4.05 %
Seq. Cash & cash equivalent Change	-16.33 %	-38.78 %	73.94 %	-1.07 %	-0.51 %

Quick Ratio first quarter 2026 Company Ranking
Within:	No.
Medical Equipment & Supplies Industry	# 32
Healthcare Sector	# 316
Overall Market	# 686

Quick Ratio Statistics
High	Average	Low
38.07	7.71	0.05
(Jun 30 2024)		(Sep 30 2014)

Financial Statements
Soleno Therapeutics Inc's Current Liabilities	$ 58 Millions	Visit SLNO's Balance sheet
Soleno Therapeutics Inc's Cash & cash equivalent	$ 256 Millions	Visit SLNO's Balance sheet
Source of SLNO's Sales		Visit SLNO's Sales by Geography

Cumulative Soleno Therapeutics Inc's Quick Ratio

SLNO's Quick Ratio for the trailling 12 Months

SLNO Quick Ratio	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months	(Mar 31 2025) 12 Months
Y / Y Current Liabilities TTM Growth	233.36 %	178.47 %	123.32 %	20.59 %	-1.6 %
Y / Y Cash & cash equivalent TTM Growth	21.97 %	43.28 %	62.33 %	76.37 %	182.34 %
Quick Ratio TTM	7.79	10.58	15.97	17.09	21.29
Total Ranking TTM	# 3167	# 1679	# 2279	# 1438	# 2053
Seq. Current Liabilities TTM Growth	32.4 %	52.52 %	30.09 %	26.9 %	10.6 %
Seq. Cash & cash equivalent TTM Growth	-2.49 %	1.03 %	21.53 %	1.88 %	14.56 %

Quick ratio ranking by company, industry and sector >> Back to SLNO Financial Strength Comparisons >> Go to Compare SLNO Quick Ratio to its Competitors

On the trailing twelve months basis Due to decrease in Current Liabilities in the Q1 2026 to $58.05 millions, cumulative Quick Ratio decreased to 7.79 above the SLNO average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Equipment & Supplies industry 171 other companies have achieved higher Quick Ratio than Soleno Therapeutics Inc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2025 from 1679 to 3167.

Explain Quick Ratio?
How much Cash & cash equivalents SLNO�s has?
What are SLNO�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Medical Equipment & Supplies Industry	# 172
Healthcare Sector	# 806
Within the Market	# 3167

trailing twelve months Quick Ratio Statistics
High	Average	Low
18.85	6.36	1.42
(Mar 31 2025)		(Jun 30 2016)

Companies with similar Quick Ratio in the quarter ending Mar 31 2026, within Medical Equipment & Supplies Industry	Quick Ratio	Mar 31 2026 MRQ Cash & cash equivalent	Mar 31 2026 MRQ Current Liabilities
Envveno Medical Corporation	11.63	$ 24.930 Millions	$ 2.143 Millions
Lemaitre Vascular Inc	11.01	$ 367.233 Millions	$ 33.369 Millions
Carlsmed Inc	9.99	$ 97.016 Millions	$ 9.715 Millions
Ceribell Inc	9.44	$ 141.184 Millions	$ 14.955 Millions
Streamex Corp	9.27	$ 30.625 Millions	$ 3.302 Millions
Perspective Therapeutics Inc	8.60	$ 270.929 Millions	$ 31.486 Millions
Delcath Systems Inc	8.42	$ 89.299 Millions	$ 10.606 Millions
Rxsight Inc	7.96	$ 217.880 Millions	$ 27.376 Millions
EBR Systems, Inc.	7.63	$ 54.194 Millions	$ 7.106 Millions
Cvrx inc	7.62	$ 72.303 Millions	$ 9.486 Millions
Talkspace Inc	7.23	$ 84.212 Millions	$ 11.655 Millions
Pulse Biosciences Inc	6.97	$ 68.319 Millions	$ 9.796 Millions
Orchestra Biomed Holdings Inc	6.89	$ 94.400 Millions	$ 13.692 Millions
Beyond Air Inc	6.59	$ 28.984 Millions	$ 4.395 Millions
Alpha Pro Tech Ltd	6.45	$ 16.883 Millions	$ 2.619 Millions
Mobia Medical Inc	5.72	$ 55.725 Millions	$ 9.750 Millions
Sharps Technology Inc	5.55	$ 12.321 Millions	$ 2.219 Millions
Omada Health Inc	5.38	$ 211.765 Millions	$ 39.327 Millions
Transmedics Group Inc	5.02	$ 461.739 Millions	$ 91.920 Millions
Heartflow Inc	5.00	$ 158.316 Millions	$ 31.636 Millions
Irhythm Holdings Inc	4.96	$ 549.620 Millions	$ 110.901 Millions
Tactile Systems Technology Inc	4.86	$ 74.993 Millions	$ 15.442 Millions
Nutriband Inc	4.81	$ 4.006 Millions	$ 0.832 Millions
Trisalus Life Sciences Inc	4.80	$ 56.553 Millions	$ 11.786 Millions
Profound Medical Corp	4.74	$ 50.295 Millions	$ 10.607 Millions
Sight Sciences Inc	4.68	$ 84.962 Millions	$ 18.163 Millions
Iradimed Corporation	4.65	$ 56.374 Millions	$ 12.118 Millions
Biolife Solutions Inc	4.44	$ 80.996 Millions	$ 18.253 Millions
Soleno Therapeutics Inc	4.40	$ 255.599 Millions	$ 58.049 Millions
Inspiremd Inc	4.40	$ 41.570 Millions	$ 9.443 Millions

Date modified: 2026-09-12T06:14:45+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.